Table of Contents

2019-2024 Global Metabolic Disorder Therapeutics Market Report (Status and Outlook)

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Metabolic Disorder Therapeutics Market Size 2014-2024
2.1.2 Metabolic Disorder Therapeutics Market Size CAGR by Region
2.2 Metabolic Disorder Therapeutics Segment by Type
2.2.1 Lysosomal Storage Diseases
2.2.2 Diabetes
2.2.3 Obesity
2.2.4 Inherited Metabolic Disorders
2.2.5 Hypercholesterolemia
2.3 Metabolic Disorder Therapeutics Market Size by Type
2.3.1 Global Metabolic Disorder Therapeutics Market Size Market Share by Type (2014-2019)
2.3.2 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (2014-2019)
2.4 Metabolic Disorder Therapeutics Segment by Application
2.4.1 Oral
2.4.2 Parenteral
2.4.3 Others
2.5 Metabolic Disorder Therapeutics Market Size by Application
2.5.1 Global Metabolic Disorder Therapeutics Market Size Market Share by Application (2014-2019)
2.5.2 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application (2014-2019)

3 Global Metabolic Disorder Therapeutics by Players
3.1 Global Metabolic Disorder Therapeutics Market Size Market Share by Players
3.1.1 Global Metabolic Disorder Therapeutics Market Size by Players (2017-2019)
3.1.2 Global Metabolic Disorder Therapeutics Market Size Market Share by Players (2017-2019)
3.2 Global Metabolic Disorder Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Metabolic Disorder Therapeutics by Regions
4.1 Metabolic Disorder Therapeutics Market Size by Regions
4.2 Americas Metabolic Disorder Therapeutics Market Size Growth
4.3 APAC Metabolic Disorder Therapeutics Market Size Growth
4.4 Europe Metabolic Disorder Therapeutics Market Size Growth
4.5 Middle East & Africa Metabolic Disorder Therapeutics Market Size Growth

5 Americas
5.1 Americas Metabolic Disorder Therapeutics Market Size by Countries
5.2 Americas Metabolic Disorder Therapeutics Market Size by Type
5.3 Americas Metabolic Disorder Therapeutics Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Metabolic Disorder Therapeutics Market Size by Countries
6.2 APAC Metabolic Disorder Therapeutics Market Size by Type
6.3 APAC Metabolic Disorder Therapeutics Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Metabolic Disorder Therapeutics by Countries
7.2 Europe Metabolic Disorder Therapeutics Market Size by Type
7.3 Europe Metabolic Disorder Therapeutics Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Metabolic Disorder Therapeutics by Countries
8.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type
8.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Metabolic Disorder Therapeutics Market Forecast
10.1 Global Metabolic Disorder Therapeutics Market Size Forecast (2019-2024)
10.2 Global Metabolic Disorder Therapeutics Forecast by Regions
10.2.1 Global Metabolic Disorder Therapeutics Forecast by Regions (2019-2024)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Metabolic Disorder Therapeutics Forecast by Type
10.8 Global Metabolic Disorder Therapeutics Forecast by Application

11 Key Players Analysis
11.1 Novo Nordisk A/S
11.1.1 Company Details
11.1.2 Metabolic Disorder Therapeutics Product Offered
11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.1.4 Main Business Overview
11.1.5 Novo Nordisk A/S News
11.2 Sanofi S.A.
11.2.1 Company Details
11.2.2 Metabolic Disorder Therapeutics Product Offered
11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.2.4 Main Business Overview
11.2.5 Sanofi S.A. News
11.3 Boehringer Ingelheim GmbH
11.3.1 Company Details
11.3.2 Metabolic Disorder Therapeutics Product Offered
11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.3.4 Main Business Overview
11.3.5 Boehringer Ingelheim GmbH News
11.4 Eli Lilly and Company
11.4.1 Company Details
11.4.2 Metabolic Disorder Therapeutics Product Offered
11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.4.4 Main Business Overview
11.4.5 Eli Lilly and Company News
11.5 Merck KgaA
11.5.1 Company Details
11.5.2 Metabolic Disorder Therapeutics Product Offered
11.5.3 Merck KgaA Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.5.4 Main Business Overview
11.5.5 Merck KgaA News
11.6 Amgen, Inc.
11.6.1 Company Details
11.6.2 Metabolic Disorder Therapeutics Product Offered
11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.6.4 Main Business Overview
11.6.5 Amgen, Inc. News
11.7 AstraZeneca PLC
11.7.1 Company Details
11.7.2 Metabolic Disorder Therapeutics Product Offered
11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.7.4 Main Business Overview
11.7.5 AstraZeneca PLC News
11.8 Actelion Pharmaceuticals Ltd.
11.8.1 Company Details
11.8.2 Metabolic Disorder Therapeutics Product Offered
11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.8.4 Main Business Overview
11.8.5 Actelion Pharmaceuticals Ltd. News
11.9 Shire PLC
11.9.1 Company Details
11.9.2 Metabolic Disorder Therapeutics Product Offered
11.9.3 Shire PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.9.4 Main Business Overview
11.9.5 Shire PLC News
11.10 AbbVie, Inc.
11.10.1 Company Details
11.10.2 Metabolic Disorder Therapeutics Product Offered
11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.10.4 Main Business Overview
11.10.5 AbbVie, Inc. News
11.11 Biocon Ltd.
11.12 BioMarin Pharmaceutical, Inc.
11.13 Bristol-Myers Squibb Company
11.14 Cipla, Inc.
11.15 CymaBay Therapeutics, Inc.

12 Research Findings and Conclusion